Pulmonary Release and Coronary and Peripheral Consumption of Big Endothelin and Endothelin-1 in Severe Heart Failure
- 5 September 2000
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 102 (10) , 1132-1138
- https://doi.org/10.1161/01.cir.102.10.1132
Abstract
Background—We investigated plasma endothelin (ET) levels in patients with congestive heart failure (CHF) during treatment for acute decompensation; we also measured imbalances in ET peptides across the pulmonary, coronary, and peripheral circulation. Methods and Results—In patients with severe CHF (n=21; cardiac index [CI], 1.9±0.2 L · min−1 · m−2; pulmonary capillary wedge pressure [PCWP], 31±1 mm Hg), vasodilation was achieved with the nitric oxide donor sodium nitroprusside (n=11) or with the α1-antagonist urapidil (nitric oxide–independent, n=10). ET concentrations were determined from arterial blood and blood from the pulmonary artery, coronary sinus, and antecubital vein. Depending on sites of measurement, baseline big ET and ET-1 levels were, respectively, 12 to 16 times and 5 to 11 times higher than in controls (n=11), and 4 to 6 times and 2 to 3 times higher than in patients with moderate CHF (n=10; CI, 2.7±0.3 L · min−1 · m−2; PCWP, 14±2 mm Hg). Patients with severe CHF demonstrated pulmonary net release and coronary and peripheral net consumption of both peptides (ie, arterial levels [big ET, 7.3±1.3 pmol/L; ET-1, 1.8±0.1 pmol/L] were higher than levels in the pulmonary artery [6.7±1.2 pmol/L; 1.3±0.1 pmol/L], coronary sinus [6.4±1.0 pmol/L; 1.4±0.1 pmol/L], and antecubital vein [6.6±1.1 pmol/L; 1.3±0.1 pmol/L]). In these patients, sodium nitroprusside (SNP) and urapidil resulted in comparable hemodynamic improvement after 6 hours (CI: SNP, 63±2%; urapidil, 72±3%; PCWP: SNP, −50±2%; urapidil, −47±2%) and a maximum decrease in ET peptides by >50%. After 3 hours, pulmonary net release and coronary and peripheral net consumption were no longer detectable. Conclusions—In patients with severe CHF, the lungs act as a producer and the heart and the periphery act as consumers of elevated circulating ETs. Short-term vasodilator therapy decreases ETs and restores their pulmonary, coronary, and peripheral balance.Keywords
This publication has 13 references indexed in Scilit:
- Hormones and Hemodynamics in Heart FailureNew England Journal of Medicine, 1999
- Expression of Endothelin-1, Endothelin-Converting Enzyme, and Endothelin Receptors in Chronic Heart FailureCirculation, 1999
- Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failureJournal of the American College of Cardiology, 1999
- Reduced pulmonary clearance of endothelin-1 in pulmonary hypertensionAmerican Heart Journal, 1998
- Human Pulmonary Circulation Is an Important Site for Both Clearance and Production of Endothelin-1Circulation, 1996
- Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction.Journal of Clinical Investigation, 1996
- Evidence for Endothelin-1–Mediated Vasoconstriction in Severe Chronic Heart FailureCirculation, 1995
- Endothelin in human congestive heart failure.Circulation, 1994
- Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide.Journal of Clinical Investigation, 1990
- Haemodynamic Effects of Urapidil in Arterial Hypertension and Congestive Heart FailureDrugs, 1988